Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (T1D) (R01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing original research addressing barriers that limit progress toward effective cell replacement therapies for type 1 diabetes (T1D). The purpose is to support research leading to the development and testing of novel and supportive technologies for the improvement of cell replacement interventions using novel biomaterials and devices for T1D treatment.Guillermo Arreaza-Rubin, M.D. | RFA-DK-18-004
Source: NIDDK Funding Opportunities - Category: Endocrinology Source Type: funding